Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR428926 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SAR428926-Escalating cohort | EXPERIMENTAL | SAR428926 will be administered intravenously up to disease progression or dose limiting toxicities |
| SAR428926 in triple negative breast cancer-Expansion Cohort 1 | EXPERIMENTAL | SAR428926 will be administered intravenously at maximum tolerated dose (MTD) up to disease progression or unacceptable toxicity |
| SAR428926 in solid tumors-Expansion Cohort 2 | EXPERIMENTAL | SAR428926 will be administered intravenously at the MTD up to disease progression or unacceptable toxicity |
| Name | Type | Description |
|---|---|---|
| SAR428926 | DRUG | Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous |
Inclusion criteria : * Patients with advanced solid tumor with no standard alternative treatment. * Availability of archived tumor tissue for SAR428926 targeted antigen testing. * For participants in the Escalation Phase: human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC), ...
SAR428926 is an investigational small molecule being studied for the treatment of Neoplasm Malignant, which refers to advanced solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
SAR428926 is being developed by Sanofi, a multinational pharmaceutical company. Sanofi is listed on the stock exchange under the ticker symbol SNY.
SAR428926 is in Phase 1 clinical development. It has completed one Phase 1 trial, and it remains an investigational drug that has not yet received regulatory approval.
SAR428926 has been studied in one clinical trial, identified as NCT02575781, titled 'A Study of SAR428926 in Patients With Advanced Solid Tumors.' This Phase 1 trial has been completed and enrolled 34 participants.
No alternative names for SAR428926 have been reported. It is identified solely by its code name SAR428926 in clinical trial registries and scientific literature.